Lixisenatide has neutral effect on heart failure and other cardiovascular outcomes.
ADA 75th Scientific Sessions 2015 Complete Coverage
Competitive bidding reduces access to diabetes supplies and increases mortality for Medicare patients.
Induced pluripotent stem cells offer a new way to study insulin resistance and other metabolic disorders in humans.
During the past 50 years, diabetes research and management has come a long way, although there is still work to be done.
Activity in certain brain regions of teenagers with type 1 diabetes was increased or decreased with hyperglycemia and hypoglycemia.
PE0139, a super long-acting basal insulin, and PB1023, a weekly GLP-1 receptor agonist, may lead to novel approach to treating diabetes.
Unsupervised closed loop insulin delivery is safe and feasible in the home setting in teens with type 1 diabetes.
Continuous glucose monitoring can reduce costs associated with diabetes and improve quality of life.
Adding lixisenatide to insulin glargine is comparable to other insulin regimens for controlling HbA1c in type 2 diabetes.
Adding liraglutide to insulin in a closed loop system may reduce postprandial hyperglycemia as well as insulin requirements, compared with insulin monotherapy.
Researchers will look at effects in people with longstanding disease,
Children may have a higher risk for fat accumulation and insulin resistance if their mothers were obese.
Food insecurity has an impact on glycemic control and vegetable consumption in Latino patients with diabetes.
Gut-based medications like GLP-1 agonists may induce weight loss by reducing cravings and increasing satiety.
GLP-1 receptor agonist may be able to reduce glycemic variability rather than a prandial insulin.
Sitagliptin did not affect rates of cardiovascular complications or heart failure in high-risk patients with type 2 diabetes.
ITCA 650, which continuously delivers exenatide subcutaneously, yielded improvements in HbA1c and body weight in patients with type 2 diabetes.
Compared with insulin glargine, once-weekly dulaglutide led to superior reductions in HbA1c in patients with type 2 diabetes.
People with type 1 diabetes treated with basal insulin peglispro vs. insulin glargine had significantly lower HbA1c levels at 26 and 52 weeks.
Achieving greater HbA1c reductions with fixed-ratio combination insulin glargine/lixisenatide did not increase rates of hypoglycemia.
Patients with type 2 diabetes and cardiovascular disease may benefit from long-term treatment with dapagliflozin.
Sign Up for Free e-Newsletters
Check out what's trending
Endocrinology Advisor Articles
- Relationship Between HbA1c and Coronary Artery Disease
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Weight Gain After Quitting Smoking May Increase Risk for T2D
- In Teens, Young Adults, High BMI May Hurt Cardiovascular Health
- Obesity Paradox Affects Type 2 Diabetes Mortality Rates
- Bi-Directional Association Observed Between Obstructive Sleep Apnea and Diabetes
- Real-World Data Show Reduced Fracture Rates in Teriparatide-Treated Osteoporosis